REPROCELL

MOLECULAR SERVICES: Real-Time PCR

Real-time PCR measures amplification cycle-by-cycle enables quantitative measurements during the exponential phase of PCR. We now utilize latest in the family of real-time PCR instruments by Applied BioSystems – the ViiA7™.

MOLECULAR SERVICES: Genomic DNA Extraction

BioServe has 20 years of experience with genomic DNA isolation from nearly all biomaterials including whole blood, blood clots, buffy coats, PMBCs, nuclear pellets, serum, saliva, mouthwash, buccal swabs, cytobrushes, plant material, cultured cells, fresh and frozen tissues and paraffin embedded tissues. Quality of DNA is determined through electrophoresis.

MOLECULAR SERVICES: RNA Extraction

BioServe has 20 years experience with RNA isolation from a variety of starting material. We have been successful in RNA extraction from whole blood, buffy coats, PAXgene tubes, lymphocytes, cultured cells, plant material, cartilage, fresh and frozen tissues and various bacteria. The quality of RNA isolated is determined using Agilent’s Bioanalyzer.

Cystic Fibrosis Genotyping Test (FDA Approved)

CLIA certified molecular diagnostic tests utilizing FDA approved GenMark Dx Tm platform. The Cystic Fibrosis Genotyping Test (FDA Approved) detects a panel of 23 recommended ACOG/ACMG mutations associated with cystic fibrosis

Warfarin Sensitivity Test (FDA Approved) : This test detects three genetic markers known to play a critical role in metabolism of and sensitivity to warfarin: CYP450 2C9(*2 and 3) and VKORC1 (-1639G>A). CLIA certified molecular diagnostic tests utilizing FDA approved GenMark Dx Tm platform.

Thrombophilia Risk Test (FDA Approved) : This test detects all four inherited genetic risk factors of thrombophilia: FV, FII, MTHFR 677 and MTHFR 1298. CLIA certified molecular diagnostic tests utilizing FDA approved GenMark Dx Tm platform

Respiratory Viral Panel (FDA Approved) : This panel is designed for simultaneous detection of 20 respiratory virus types and subtypes. CLIA certified molecular diagnostic tests utilizing FDA approved GenMark Dx Tm platform.

Plavix Sensitivity Testing: This test is designed for detection and genotyping of the *2, *3, *4, *5, *6 ,*7, *8, *9, *10, *13 and *17 alleles of the cytochrome P450 2C19 gene locus. CLIA certified molecular diagnostic tests utilizing FDA approved GenMark Dx Tm platform.

Pain Management: This test is designed to test the variations in CYP 3A4 and CYP 3A5 that can help predict the effectiveness of the drugs involved in pain management. CLIA certified molecular diagnostic tests utilizing FDA approved GenMark Dx Tm platform.

Human Biorepository

BioServe’s Global BioRepository is one of the largest commercial human tissue banks in the world. With more than 600,000 human serum, DNA, RNA, and FFPE samples, from over 120,000 patients on four continents. BioServe also continues to establish procurement partnerships with speciality clinics around the United States in a number of indications/diseases for prospective sample collection.

Exclusive provider of the Stemgent® StemRNA™ 3rd Gen reprogramming technology — the most rapid, robust, and clinically relevant integration-free method on the market, allowing REPROCELL to deliver iPSCs in around half the time of its competitors, even from refractory patient lines. Custom iPSC production services include:

• Fresh, normal or diseased tissue available through our custom collection network
• Establishment of patient-derived primary somatic cell lines as part of the standard service
• Reprogramming of multiple human and non-human cell types
• Cryopreserved patient-derived primary cells and iPSCs expanded and provided
• Milestone achievements for flexible project customization and fair value

We have extensive experience with differentiation of iPSCs into hepatocytes, cardiomyocytes and neuronal cells (mixed progenitors, dopaminergic, sensory). REPROCELL also has collaborations with key academic labs and ongoing projects related to several other differentiated cell types. This service can be used in conjunction with our iPSC Reprogramming Services.

Novel Alvetex-based 3D assay for inhibition and recovery of Neurite Outgrowth. Using TERA-2 or ReproNeuro™ iPSC-derived Human Neurons (wild-type, Alzheimer's presinilin-2 patient and presinilin-1 mutant). Explore physiological and pathological ECM coatings (laminin, CSPGs), known pathway inhibitors and therapeutic lead compounds.

Human Mucosa (ileum, trachea) Ion Channel Activity Assays

This assay assesses whether a test compound causes a change in short circuit current across healthy human tracheal mucosa or healthy human gastrointestinal mucosa. Controls include isoprenaline, amiloride and cholera toxin.

Human Ex-vivo Culture Inflammation Assays

These assays assess the effect of test compounds on ex-vivo cultures of Human biopsies from skin, GI and lung tissue, from healthy and diseased patients. Diseased tissues that can be accessed include psoriasis, atopic dermatitis, asthma, COPD, Ulcerative Colitis and Crohn's Disease. Inflammation can also be induced via pre-treatment of healthy biopsies with LPS, TH-17 cocktail or TH-2 cocktail. Common endpoints are ELISA and gene expression.

This assays assesses the effect of test compounds on viability, cytokine release, as well as artery and airway diameter, in Human precision-cut lung slices. Treatments include LPS and isoprenaline.

This assay assesses the permeability of test articles across healthy human gastrointestinal mucosa. It is possible to assess permeability across multiple regions of the GI system, eg. stomach, jejunum, ileum, colon.

This assay assesses whether test compounds cause bronchoconstriction in human airways, using denuded secondary, tertiary or lower airways from healthy, asthma or COPD human donors. Controls include carbachol, histamine, acetylcholine, leukotriene D4, U46619.

This assay assesses whether test compounds cause bronchodilation in human airways, using denuded secondary, tertiary or lower airways from healthy, asthma or COPD human donors. Controls include isoprenaline, formoterol, salbutamol, salmeterol.

Human Cardiac Muscle Contractility Assays

This assay assesses whether test compounds cause an increase in contractile force in electrically stimulated human atrial or ventricular muscle, from normal or failing hearts. Targets include 5-HT receptor, adrenoceptors, PDE3 receptor, acetylcholine receptor.

Human Uterus Contractility Assays

This assay assesses whether test articles cause an increase, or a decrease, in spontaneous contractile activity in isolated human uterine tissue. Controls include oxytocin, vasopressin, isoprenaline, isradipine and SNP.

Human Gastrointestinal (stomach, colon) Muscle Contractility Assays

This assay assesses whether test articles cause a change in contractile force on electrically stimulated human stomach or colon. Controls include galantamine, meptanizol and erythromycin.

Human Urinary (Ureter, Bladder, Urethra) Contractility Assays

This assay assesses whether test articles cause contraction in isolated human urethra, or cause relaxation in isolated human ureter or human bladder strips. Controls include epinephrine, isoprenaline and isoproterenol.

This experiment assesses whether test articles cause vasoconstriction in human coronary arteries, sub-cutaneous resistance arteries or saphenous vein. Ask us for other vascular beds. Targets include receptors for angiotensin, 5-HT, opiods, vasopressin, oxytocin, phenylephrine and prostanoids

The experiment assesses whether test articles cause vasodilatation in human chorionic plate arteries, skeletal muscle arteries or sub-cutaneous resistance arteries. Ask us for other vascular beds. Tragets include receptors for bradykinin, PDE3, PDE5, acetlycholine, SNP, vasopressin and oxytocin.

Biology Services